Newsroom

Skyrocketing specialty drug cost hurts wallets

The rising cost of specialty drugs to treat complex, chronic or life-threatening conditions has the potential to break the pocket books of businesses, consumers, insurance companies and the state, according to Milam Ford of Blue Cross and Blue Shield of Louisiana.

Read more

PRESS STATEMENT: Survey Finds Early Primary State Voters Looking for Action on Prescription Drug Prices

A recent study of over 2,500 voters in Iowa, South Carolina and New Hampshire found that prescription drug prices are becoming a hot political issue in these early primary states. The study was conducted by Morning Consult on behalf of the Campaign for Sustainable Rx Pricing.

Read more

How to Lower Specialty Drug Prices

We need to make clear that monopoly grants come with responsibility and accountability, and that competition is more important to the public than a blank check for innovation we cannot afford.

Read more

CalPERS approves 7.2% increase in HMO rates as drug costs climb

CalPERS said it spent nearly $40 million for Sovaldi on plans run by Blue Shield of California, Kaiser Permanente and CVS Health.

Read more